Millions of Brits can skip the GP queue this winter and head straight to their local pharmacist. Amid warnings a ‘quad-emic’ of flu, covid, RSV and norovirus, doctors and hospital medics are battling ...
The aggregate gross proceeds to the Company from the offering were approximately $2.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company ...
Clarametyx Biosciences Inc. ("Clarametyx"), a biotechnology company developing immune-enabling biologic technologies to combat serious infections associated with biofilms, today announced that CARB-X ...
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection: Staten Island, New York Tuesday, January 7, 2025, 18:00 ...